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The negative PV/LA gradient AccA preceded ths A-w~ve by 105:1:49 ms 
and had an amplitude of 1.1 :E 0.52 mmHg. The calculated inertsnce (M) of 
PV fl0w was 4.77 =E 1.4 cm. 
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Conclusions: Inertial forces contribute significantly to PV/LA gradients and 
therefore must be considered when deriving LA pressure from PV flow profiles 
in the cli0leal setiing. 
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OllUazem as AdJun~ Tre. atnl_ent in Idlopalhic Dilated 
Cardiomyopathy. Resuns o!  the DlOi-Trlal 
Hans R. Figulla, Frank GtetZen, Uwe Zeymer, Marlin Ralber, 
Johannes Hegselmann, Reinhild Soballa, Reinhard Hilgem for the 
DIOI-Study Group. Univers~ts.Kliniken GOffingeno Germany 
Background: In idiopathic dilated cardiomyopathy (IDC) evidence is arising 
that calcium antagonists may have beneficial effects on virus induced car- 
diopathology, alcohol toxicity, micrecirculatory disorders and impaired cal- 
cium cycling. Thus, the effect of diltiazem on IDC was investigated. 
Methods: The diltiazem in dilated cardlomyopathy (OiOi) trial was a ran- 
domized, double-blind, placebo-controfled, multicenter trial on 186 patients 
(n = 92 dlltiazem, n = 94 placebo) with IDC. The effect of adjunct diltiazem (60 
to gO mg rid) to standard treatment was investigated udng a 24 months tudy 
pedod. The hemodynamic and cl?nioal status of all patients was assessed 
every 6 months. 
Results: Within 24 months 33 pts. dropped out of the study 153 pts. finished 
the study protocol. 27 pts, died or were heart transplanted, 16 in the placebo 
group, 11 in the diltlazem group. The transplant listing f~e suwiva] rate 
was 85% for diltiazem and 80% for placebo (p = 0.442). After ~4 months 
exclusively diltiazem and not placebo increased significantly carcfiac index 
at rest (p = 0.01) ~nd under work load (p = 0.02) systolic and diastolic Mood 
pressure (p = 0.003, p = 0.004) slroke volume index (p = 0.003) and stroke 
work index (p = 0.(300) a,d lowered putmonary artery pressure at work load 
(p = 0.007) and hea~1 rate (p = 0.001). In addition diltiazem increased the 
exercise capacity (p = 0.002) as well as the patients' subjective wall being (p 
= 0.01 ). Adverse reactions ware minor, and evenly disth'buted in both groups, 
except an increase of the PQ-tntsNal in the diltiazem gm~ 
Conclusion: The adjunct herapy of IDCwith diltiazem has benof¢ial effects 
of the patients' hemodynamlc-, i mctional-, and subjective status, without 
(feletsdous on transplant listing free survival. 
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~ Sequential Neurohormonsl Response to Felodlpine 
In Enalapdl-Treated Heart Failure: V.HeFT III 
Jay N, Cohn, Dlanne L Judd for the V-HeFT Ill Study Group. V A. Med/cal 
Center and University of Minnssot~ Minneapolis, MN 
Plasma levets of norep~nsphrine (PNE) and atdal .a~iuretic pept~ (ANP) 
are correlated with mortality dsk in patients with heart failure (HI=). In the 
~econd Vasodilator.Heart Failure Tdal (V-HeFT II) PNE was suppmsesd 
for the first 1-2 years of fo~',w-up by ana]at~l conT, ared to hydralazine and 
isasod)ide d~ftlt fate therapy, but PNE later "esoaped" and 4-year mortality was 
> 40%. Newer more vaSoseie~ caldum antagon~s have besn n~ted  
in pml im~ s~uofes to fesufl In ~ ~ in HF. In V41eFT Ill 
e,alstx,'~-emd ,m~ pa~e,~  oaro'iac e,~,gemem or ~ and 
ex~dea intolerance were remlareized to ~ ti'm vasaseie~ve ~
am~o,-~ fekxk~ (F) vs. p~cebo (P). PNE and ANP were mea~m~ 
sequ~W, aG,/to detmmtne ff F hsd an infk~-,~ on newobormm~ imuta~n 
that migM inf~en~ bn0-tarm mottsFty. PNE as beesm~ in F (n - 20@ was 
s~ghgy higbef (535 i~ .  than in P (n = 207, 478 pg/ml] (p = 0.03) wh~eas 
ANPIn F (n- ~90. ~30 l~n@ was aln~r to thaZ In P (n- 20~-, it9 portal) Lo 
= NS). During fcil~v-up at I month, 3 months, I year and 2 years the change 
in PNE was sire,at in F and P with progressive increases in both groups. 
In contrast a wogressive increase in ANP in P was sV~ , , '~y  suppressed 
at 1 month by F (-2.9 ~ ?.5[SEM]pg/ml vs +27.2 :t= 8.8 pg/ml, p = 0.01). 
Thereafter, the ri~ in ANP was eimgar in F and P. 
Therefore F, which d'~ not alter mortality in V-HeFT II1, did not affect the 
progressive dee in PNE but prodt~l  ~<~ort.lem~ Jnhib~n of ANP, which 
probably reflects a hemodynamic action of tb~ dn~...TP~.e,'J~t~P  th.-'f 
F does not alter the natural history of enalapril-b'eated HI =. 
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~ Flolae Imemational Randoml;md Survival Trial 
(FIRST): Rna| Re.suits 
Robert M. Calilf, Kirkwood F. Adams, Paul W. Arms~ng, Herald Oar/us, 
Mihai Gbeorghiede, Etteen Handberg, Frank E. Han~ll, Jr., William 
J. McKenna, Steven E. McNulty, Kevin Schulmen, Jorge Soler-Soler, 
Kad Swed~rg, Barry Uretsky, William S. Wheeler, Faiez Zannad. Duke 
Un ive~ Medical Center, Durham, NC 
Patients w~ end-stage heart failure (ESCHF) pose a significant herapeutic 
dilemma ff they are not canal/dates for transplantation because of their very 
high mortality and poor quality of life. We randomized 471 such patients to 
epoprostenei otto standard therapy. Ent~ criteria included: LV ejection frac- 
tlen < 25%, NYHA class III or W CHF, pulmooa~j c;~oilia~y wedge pressure 
> 15 mm Hg, and cardiac index < 2.5 Umin/rcF. The •al was stopped pre- 
maturely on recommendation fthe Data and Safety Monit0dng Committee. 
Clinical events (Kapian-Maier 6-month estimates) inchKled: 
EpOl~omno! (n - 237)_ Co~I~ol (n = 234) 
Death 53% 41% 
Worsening CHF 56% 56% 
IV vasoactk, e drugs 51% 42% 
Sudden des~ resuscitation 11% 2% 
6-n-Jnute walk (3 menlhs)* 297 (185. 359)  305(220.339) 
EUROQOL (3_mon~.)t 57 (44. 80) 60 (45. 75) 
"median (/nterquartTe range) melen~ ?merlin score (interquarb'le range) on a qual~-of- 
lif= b~xtex from 0-100; 100 ~ opt/rrmn~ 
Conc/us?ons: Potent vasndiiattan with a prostaglandin does not improve 
outcomes in ESCHF. aithough a continuous home Infusion is leasibte. 
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~734~ I The Nm'WORK S~dy. The EWect of OO.e of an 
. . . .  ACllL~nhJbltor on Outcome/it  Patients With Heart 
Failure 
Philip A. Poole-Wifsan on behalf of the NETWORK I ~ m .  Nat/one/ 
Heart & lung Institute, In~ College, london, UK 
Mortality of patients with OHF has been shown to be iml0roved by the add/tion 
of enaial~l to conventional therapy, with a ~uget dese of 20 n~ enaial~l 
daily, The pdma~ objective of this ~ was to inv~"t~e the dose re- 
sponse relationship of enalalm'l, in terms of a composite ndpoint of death, 
hea~ falture-relaled hoepitalJsatk~ or wo~ing  heart failure. 1532 patiec~s 
with CHF of mare than NYHA ctsas I sevedty v,~ce mndomiasd to alx manths 
t ~  with 2.5 m~ bkl, 5 mg bid or 10 m~ bid In a~itlon to other beart 
f~'lum treatment. Median age was 70 year~, 64% were male and IHD was 
the effology In 68%. NYHA claes II accounted for 65%, wfth a me~ LVEOD 
of 59 ram. More than 88% of the palients were on 40 mg furosemide (or its 
equivalent) or more. At least 85% of each group ashleved the intondnd dose. 
Other thas deaill, treaiment wflhdrawals were 16%, 16% and 23% raspS. 
Ik~/. Al~r 6 man[ha, the number of pdma~ endpcints and the compommts 
of mat e.dpo~ ware: 
2~5 mgl~d 5 m0bld 1Omgt~ 
n-506 nm510 n-516 
e..Z~oo~ E~p~ ~ SS 72 
Oea~h 14 tl 12 
CHF-~dated hasp 20 23 32 
Wom,~CHF 28 S~ 2S 
Total 0'ealfls 2t 17 15 
The mtstive risk of a pdmary e '~ In the 10 mg I~1 group, Compared 
wi~ 1~ 2.5 mg I~1 d~ze w'~s 1.14. The 95% cenfldence Infefvals were wid~ 
(0.83~1.5"/). ~ was weU zok~ m an eves ~roups. ~ conclusion, 
t~s stoo~/ha3 fa~d ~ demonsUa~ a ¢bse raspoase P~s~,  but ~ 
wkle c~r~-~.~ In ten~ mean t l~  a ~ cenoot be exckcled. 
